

Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

December 23, 2019

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip code: 500672

- Sub.: 1. <u>Intimation of meeting of the Board of Directors of Novartis India Limited</u> ("the Company")
 - 2. Closure of Trading Window
- Ref.: 1. Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
 - 2. <u>Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations</u>, 2015

Dear Sir/ Madam.

Please be informed that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, February 11, 2020, to *inter alia* consider the Unaudited Financial results of the Company for the third quarter and nine-months ending on December 31, 2019 ("said results").

In this connection, further note that pursuant to the Company's Code of Conduct to regulate, monitor and report share trading by Insiders ["the Code"], the trading window for dealing in securities of the Company shall remain closed from Wednesday, January 1, 2020 to Thursday, February 13, 2020 (both days inclusive).

The same is being duly communicated to all the Designated Persons under the Code which is available on the Company's website i.e. www.novartis.in.

This is for your information.

Thanking You.

Yours sincerely,

For Novartis India Limited

Trivikram Guda Company Secretary & Compliance Officer